Evolva
Provides products that can contribute to health, wellbeing and sensory enjoyment.
Launch date
Employees
Market cap
AUD8.8m
Enterprise valuation
AUD26m (Public information from Sep 2024)
Share price
CHF0.91 EVE.SW
Company register number CH-170.3.027.314-6
Reinach Canton of Basel-Landschaft (HQ)
Financials
Estimates*
CHF | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | 11.6m | 7.5m | 9.9m | 15.5m | 23.4m | 45.8m | 67.6m |
% growth | 45 % | (35 %) | 31 % | 57 % | 50 % | 96 % | 48 % |
EBITDA | (16.1m) | (20.8m) | (31.9m) | (35.3m) | - | - | - |
% EBITDA margin | (139 %) | (276 %) | (322 %) | (227 %) | - | - | - |
Profit | (21.6m) | (29.9m) | (41.3m) | (43.4m) | - | - | - |
% profit margin | (187 %) | (396 %) | (418 %) | (279 %) | - | - | - |
R&D budget | 13.7m | 13.6m | 22.4m | 23.6m | - | - | - |
R&D % of revenue | 118 % | 180 % | 227 % | 152 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$10.3m | Series A | ||
$5.0m | Grant | ||
$27.5m | Post IPO Equity | ||
N/A | Grant | ||
CHF12.0m | Post IPO Equity | ||
CHF12.0m | Post IPO Debt | ||
* | N/A | CHF6.3m | Post IPO Equity |
* | $540k | Grant | |
* | CHF12.0m | Post IPO Convertible | |
* | $23.5m Valuation: $23.5m | Acquisition | |
Total Funding | AUD47.3m |